Bacterial Infections the 'Second Leading Cause of Death Worldwide'

Hand washing is advised to prevent infection with the pathogens S. aureus and E. coli, which are behind a huge number of deaths every year JENS SCHLUETER AFP/File
Hand washing is advised to prevent infection with the pathogens S. aureus and E. coli, which are behind a huge number of deaths every year JENS SCHLUETER AFP/File
TT

Bacterial Infections the 'Second Leading Cause of Death Worldwide'

Hand washing is advised to prevent infection with the pathogens S. aureus and E. coli, which are behind a huge number of deaths every year JENS SCHLUETER AFP/File
Hand washing is advised to prevent infection with the pathogens S. aureus and E. coli, which are behind a huge number of deaths every year JENS SCHLUETER AFP/File

Bacterial infections are the second leading cause of death worldwide, accounting for one in eight of all deaths in 2019, the first global estimate of their lethality revealed on Tuesday.

The massive new study, published in the Lancet journal, looked at deaths from 33 common bacterial pathogens and 11 types of infection across 204 countries and territories, AFP said.

The pathogens were associated with 7.7 million deaths -- 13.6 percent of the global total -- in 2019, the year before the Covid-19 pandemic took off.

That made them the second-leading cause of death after ischaemic heart disease, which includes heart attacks, the study said.

Just five of the 33 bacteria were responsible for half of those deaths: Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae and Pseudomonas aeruginosa.

S. aureus is a bacterium common in human skin and nostrils but behind a range of illnesses, while E. coli commonly causes food poisoning.

The study was conducted under the framework of the Global Burden of Disease, a vast research program funded by the Bill and Melinda Gates Foundation involving thousands of researchers across the world.

"These new data for the first time reveal the full extent of the global public health challenge posed by bacterial infections," said study co-author Christopher Murray, the director of US-based Institute for Health Metrics and Evaluation.

"It is of utmost importance to put these results on the radar of global health initiatives so that a deeper dive into these deadly pathogens can be conducted and proper investments are made to slash the number of deaths and infections."

The research points to stark differences between poor and wealthy regions.

In Sub-Saharan Africa, there were 230 deaths per 100,000 population from bacterial infections.

That number fell to 52 per 100,000 in what the study called the "high-income super-region" which included countries in Western Europe, North America and Australasia.

The authors called for increased funding, including for new vaccines, to lessen the number of deaths, also warning against "unwarranted antibiotic use".

Hand washing is among the measures advised to prevent infection.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”